Document:

Addendum No. 4 to Amended and Restated Master Services Agreement

 EXHIBIT 10.63 
 ADDENDUM No. 4 TO 
 AMENDED AND RESTATED MASTER SERVICES AGREEMENT 

 THIS ADDENDUM No. 4 (the “Addendum”) to the AMENDED AND RESTATED MASTER SERVICES AGREEMENT dated as of May 31, 2005, as
amended (collectively, the “Agreement”), by and between EXPRESS SCRIPTS SPECIALTY DISTRIBUTION SERVICES, INC. (“ESSDS”) and ORPHAN MEDICAL, INC. (“Orphan Medical”) and assigned to JAZZ
PHARMACEUTICALS, INC. (“Jazz Pharmaceuticals”), is entered into as of July 16, 2007 (the “Effective Date”) by and between ESSDS and Jazz Pharmaceuticals. Capitalized terms not otherwise defined herein shall
have the same meanings as in the Agreement. 
 RECITALS 
 WHEREAS, Jazz Pharmaceuticals desires ESSDS to provide certain Nursing Program Services for its product, Xyrem; 
 WHEREAS, the parties are discussing ways to enhance the existing Xyrem Success Program, including the possible adoption of a specialty pharmacy
HUB program, and ESSDS desires to now hire three additional full time employees in response to these discussions; 
 WHEREAS,
the parties desire to include and describe in more detail the provision by ESSDS of certain Nursing Program Services; 
 WHEREAS, the
parties desire to include and describe in more detail the responsibilities of the three full time employees that ESSDS desires to hire and Jazz Pharmaceuticals’ payment obligation regarding same; 
 WHEREAS, Section 10.10 of the Agreement provides that the Agreement may be amended by a written instrument signed by both parties; and

 WHEREAS, the parties desire to supplement the Agreement as provided herein. 
 NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein and in
the Agreement, the parties hereto agree as follows: 
 AGREEMENT 
 1. Incorporation of Recitals. The Recitals are hereby incorporated into the Addendum. 
 2. Definitions. As used in this Addendum, the following term (and the plural thereof, when appropriate) shall have the meaning set forth
herein, except where the context makes it clear that such meaning is not intended: 
  

	 	a.	“Nursing Program Services” shall mean those services set forth in Exhibit A. 

  

 1 
 [ * ]
= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended.

	 	b.	“FTE Services” shall mean those services set forth in Exhibit B. 

  

	 	c.	Capitalized terms used herein but not defined herein shall have the meaning ascribed to them in the Agreement. 

 3. Performance of Nursing Program Services. ESSDS shall perform the Nursing Program Services set forth in Exhibit A for Jazz
Pharmaceuticals for its product, Xyrem. ESSDS agrees to perform such Nursing Program Services with due care in accordance with the standards and practices which are generally accepted in the industry and exercised by other persons engaged in
performing similar services in the local area and in accordance with all applicable federal and state laws and regulations. 
 4.
Performance of FTE Services. ESSDS will hire a HUB Trainer, a Xyrem Account Director, and a Xyrem Operations Director to perform the FTE Services set forth in Exhibit B for Jazz Pharmaceuticals in connection with the Xyrem
Success Program. ESSDS agrees to perform such services with due care in accordance with the standards and practices which are generally accepted in the industry and exercised by other persons engaged in performing similar services in the local area
and in accordance with all applicable federal and state laws and regulations. 
 5. Termination. Either party may terminate
this Addendum on thirty (30) days’ prior written notice to the other party, provided, however, that neither party may terminate this Addendum prior to December 31, 2007. 
 6. Fees. Jazz Pharmaceuticals shall pay ESSDS the monthly fees described in
Exhibit C in consideration of the performance of Nursing Program Services and the FTE Services. The fees described on Exhibit C shall constitute full and complete payment for performance of the Nursing Program Services and the FTE
Services under the Agreement. Payment of the fees for the FTE Services will commence 30 days following the hire by ESSDS of individuals to perform the FTE Services; payment for the Nursing Program Services will commence on September 1, 2007.
ESSDS shall invoice Jazz Pharmaceuticals monthly. Jazz Pharmaceuticals agrees that: (1) the fees for the Xyrem® Nursing Program Services and the FTE Services shall constitute
compensation for bona fide services; (2) the Xyrem® Nursing Program Services and FTE Services are not intended to serve, either directly or indirectly, as a means of marketing any Jazz
Pharmaceutical product, (3) the Xyrem® Nursing Program and FTE Services are not intended to diminish the objectivity or professional judgment of ESSDS; (4) the Xyrem® Nursing Program and FTE Services do not involve the counseling or promotion of any off-label use of Jazz Pharmaceutical products; (5) the fees for the Xyrem® Nursing Program Services and FTE Services are not intended in any way as remuneration for referrals or for other business generated; and (6) any fees for the Xyrem® Nursing Program Services and FTE Services represent fair market value for these services based 

  

 2 
 [ * ]
= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended.

 
on arms-length negotiations. The parties acknowledge that fees paid for the Xyrem® Nursing
Program Services and FTE Services pursuant to this Agreement are not intended in any way as a payment related to drug formulary or drug formulary activities and have not been negotiated or discussed between the parties in connection with any such
drug formulary or formulary activities. 
 7. Miscellaneous. 
  

	 	a.	Except as expressly set forth in this Addendum, all of the terms and conditions of the Agreement shall remain in full force and effect. 

  

	 	b.	To the extent there is a conflict between the terms and conditions of this Addendum and the terms and conditions of the Agreement, this Addendum shall control.

  

	 	c.	This Addendum may be executed in one or more counterpart copies, each of which shall be deemed an original, and all of which shall together be deemed to constitute one agreement.
Facsimile execution and delivery of this Addendum is legal, valid and binding execution and delivery for all purposes. 

 [SIGNATURE PAGE FOLLOWS] 
  

 3 
 [ * ]
= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended.

 IN WITNESS WHEREOF, the parties have executed or caused this Addendum to be executed effective as of the Effective Date
of this Addendum. 
  

									
	 EXPRESS SCRIPTS SPECIALTY
 DISTRIBUTION
SERVICES, INC.
	 		 	JAZZ PHARMACEUTICALS, INC.
					
	By:	 	/s/ Glen H. Bogner	 		 	By:	 	/s/ Carol Gamble
	Its:	 	Vice President	 		 	Its:	 	SVP and General Counsel

  

 4 
 [ * ]
= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended.

 EXHIBIT A 
 NURSING PROGRAM SERVICES 
 Population 
  

	 	•	 	 Patients to whom Nursing Program Services will be offered include all newly enrolled patients. Patients and Physicians will have the option to opt out of the
program at anytime during their course of therapy. 

 Staffing 
  

	 	•	 	 ESSDS will staff and support the Nursing Program Services with a pool of [ * ] to [ * ] nurses whose first priority shall be the Nursing Program Services. These
nurses will devote the majority of their time to providing Nursing Program Services. 

 Contact 
  

	 	•	 	 The designated nurses will contact all newly enrolled patients at designated intervals over the course of the patient’s Xyrem therapy. There will be four
(4) scheduled calls with the patient. Outbound scripted phone calls shall be made by a designated nurse at the following frequency: 

  

	 	1.	In the event a patient expresses concerns to the reimbursement specialist regarding initiating therapy that could specifically be addressed by nurse consultation, the reimbursement
specialist may soft transfer the patient to a nurse. 

  

	 	2.	The first scheduled call, however, will occur at calendar business day [ * ] after the time of therapy dispense. 

  

	 	3.	The second scheduled call between [ * ] calendar business days following therapy initiation. 

  

	 	4.	The third scheduled call between [ * ] calendar business days following therapy initiation. 

  

	 	5.	The fourth scheduled call between [ * ] calendar business days following therapy initiation. 

 The patient may contact the nurse at other intervals throughout the program. Additionally, it may be necessary for the nurse to contact the patient’s
physician throughout the program for clarification of orders and/or compliance issues. 
 Documentation 
  

	 	•	 	 ESSDS will document all contact with the enrolled patients. 

  

 A-1 
 [ *
] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 Reporting 
  

	 	•	 	 ESSDS will provide a monthly report to Jazz Pharmaceuticals. The report requirements, codes, format, and scripting is provided in Exhibit D. It is intended that
such information will be de-identified under HIPAA, and Jazz Pharmaceuticals represents that it will not use such information to attempt to identify the identity of any patient. 

  

 A-2 
 [ *
] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 EXHIBIT B 
 FTE SERVICES 
 HUB Trainer 
 The Hub Trainer will provide all training relating to fulfillment and distribution of Xyrem. The Hub Trainer will dedicate [ * ]% of their time to training related to the Xyrem Success Program. 
 Xyrem Account Director 
 The Xyrem Account Director will be designed
as the single point of contact for Jazz Pharmaceuticals and will be responsible for optimizing the effectiveness of the enhanced Xyrem Success Program. The Xyrem Account Director will dedicate 100% of their time to the Xyrem Success Program.

 Xyrem Operations Director 
 The Xyrem Operations
Director will serve as a single point of contact for the Xyrem Account Director. The Xyrem Operations Director will dedicate 100% of their time to the Xyrem Success Program. 
 All references above to the Xyrem Success Program include any enhancements subsequently made to that program, including adoption of a specialty pharmacy Hub program. 
  

 B-1 
 [ *
] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 EXHIBIT C 
 FEES 
  

					
	 Services
	  	Fees	 
	 Monthly Nursing Program Services Fee
	  	$	[	*]
	 Monthly FTE Fee
	  	$	[	*]*

 The fee schedule listed above is subject to the following qualifications: 
  

	 	•	 	 Pricing will be reviewed 6 months from the start date of the program. 

  

	 	•	 	 The pricing review will take into account the necessary staffing involved and any necessary program enhancements such as reporting, IT development and programming,
process flows, new indications, increase in sales, and any other circumstances that are mutually agreed upon that might involve the necessary staffing levels to change. The pricing will be reflected in a change to the FTE rates associated with the
necessary job level and skill set required to perform the job function. 

  

	 	•	 	 Any necessary changes to the data requirements post implementation and addendum execution will be billed at a rate of $[ * ] per hour for IT development and
programming time. 

  

	 	•	 	 * The monthly FTE Fee assumes that all three FTEs are hired and working at the same time. In the event they are not, the Monthly FTE Fee will be prorated based upon
which of the three positions are actually filled, as follows: 

  

	 	•	 	 Hub Trainer, $[ * ] per month; 

  

	 	•	 	 Xyrem Account Director $[ * ] per month; and 

  

	 	•	 	 Xyrem Operations Director $[ * ] per month. 

  

 C-1 
 [ *
] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 EXHIBIT D 
 MONTHLY REPORTS 
  

					
	 Frequently Asked Questions-Monthly Patient
Questions
	  	 Definition
	  	Number Asked Monthly
			
	Pill vs Liquid	  	Why liquid medication? Why can’t make it in pill form?	  	
			
	Dosing	  	Why 2 doses? Why can’t it last longer so don’t have to take second dose?	  	
			
	Prescribed vs Street	  	What is difference between “street” GHB and prescribed Xyrem?	  	
			
	Sleep Cycle/Stages	  	What are normal stages of sleep?	  	
			
	How works	  	How does Xyrem help Narcolepsy w/Cataplexy, EDS?	  	
			
	Withdrawal	  	Will I have withdrawal symptoms if I stop taking?	  	
			
	Interactions - TF to RPh	  	Questions regarding other Xyrem interaction with other medication? Transfer call to pharmacist.	  	
			
	Safety-Other Med Conditions	  	Is it safe to take Xyrem when I also have heart disease, lung disease, bipolar disease, hypertension, etc.	  	
			
	Awake/Emergency	  	Will I be able to wake up for an emergency, children crying, alarm clock etc.	  	
			
	Common Side Effects	  	What are the common side effects?	  	
			
	TF (transfer call) to Medcomm	  	Experiencing common or uncommon side effects, any new symptom if associated with taking Xyrem, death.	  	
			
	Central Pharmacy	  	Why can’t I get this at my pharmacy where I get all my other medications?	  	
			
	Alcohol	  	Is it safe to drink alcohol when taking Xyrem?	  	
			
	Travel	  	How do I travel with Xyrem? Any special requirements when traveling with Xyrem?	  	
			
	Skipping Doses	  	Is it OK to skip doses (daily or second dose)?	  	
			
	Ship/Delivery - TF to Pharmacy	  	Shipment or delivery questions. Transfer call to Pharmacy	  	
			
	Cost/Bill - TF to Reimbursement	  	Reimbursement questions. Transfer call to Reimbursement Specialist.	  	

  

 D-1 
 [ *
] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

					
	 Scripting for Calls
 Patient Response-Monthly
	  	 	  	Number Asked Monthly
	New Patient 1st call	  		  	
			
	Aware preparation?	  	Yes/No	  	
			
	Aware frequency?	  	Yes/No	  	
			
	Aware titration?	  	Yes/No	  	
			
	Delay start?	  	Choices: Moving, Vacation, Work/School, Talk to MD, Wean other meds, Home Alone, Unspecified	  	
			
	Follow up calls post 1st call	  		  	
			
	 Taking as prescribed?
 Sleeping longer
periods?
	  	 Yes/No
 Yes/No
	  	
			
	Feel more rested?	  	Yes/No	  	
			
	Skipping doses?	  	Yes/No	  	

 If patient indicates they are no longer taking Xyrem during one of the above scheduled nurse calls, the nurse will
contact the physicians’ office in a timely manner and alert them to this finding. 
 Glossary of Call Type Codes: 
  

			
	 Call Type Code
	  	 Call Type Definition

	IN-MD	  	Inbound physician office call
	IN-PT	  	Inbound patient call
	Ship-1	  	New Patient Call-1st attempt
	Ship-2	  	New Patient Call-2nd attempt
	OPT-MD	  	Physician opting patient out of program
	OPT-PT	  	Patient opting out of program
	 DC-MD
 10D-1
	  	 DC Xyrem-physician office notified
 10-14 Days on
Xyrem-1st attempt

	10D-2	  	10-14 Days on Xyrem-2nd attempt
	25D-1	  	25-30 Days on Xyrem-1st attempt
	25D-2	  	25-30 Days on Xyrem-2nd attempt
	55D-1	  	55-60 Days on Xyrem-1st attempt
	55D-2	  	55-60 Days on Xyrem-2nd attempt

 Monthly Number of Calls Reporting Format: 
  

			
	 Call Type
	  	Number
of Calls
	 IN-MD
	  	0
	 IN-PT
	  	0
	 Ship-1
	  	0
	 Ship-2
	  	0
	 OPT-MD
	  	0
	 OPT-PT
	  	0
	 10D-1
	  	0
	 10D-2
	  	0
	 25D-1
	  	0
	 25D-2
	  	0
	 55D-1
	  	0
	 55D-2
	  	0
	 Total
	  	0

  

 D-2 
 [ *
] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 Nurse Opt Out Data Reporting Format 
  

															
	 *Patient ID
	  	**Physician
First Name	  	**Physician
Last Name	  	 *Physician
 CHIP ID
	  	 *Physician
 JPI ID
	  	Requestor	  	Current Case Status	  	Total
Fills
		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  	

  

	*	The Patient will be de-identified 

  

	**	Those physicians residing in NH will not be reported on 

 Monthly Nursing Summary Reporting Format: 
 Nursing Summary 
  

					
	 	  	Patients
	Number of Patients Enrolled from MM/DD/YYYY through MM/DD/YYYY (since nursing program launch date until term of program)	  	0
	Number of Patients Currently Participating (all newly enrolled patients from nursing program launch date less patient and physician opt outs until term of program)	  	0
	Number of Patients Shipped through MM/DD/YYYY (since nursing program launch date until term of program)	  	0
	 Percentage of Patients Shipped
	  	#DIV/0!
	 Average Number of Fills per Patient
	  	0.00
	Number of On Hold Patients	  	0
	 Percentage of On Hold Patients
	  	#DIV/0!
	Number of Disenrolled Patients	  	0
	 Percentage of Disenrolled Patients
	  	#DIV/0!

  

					
	 	  	Count	  	%
	 Disenrolled Patients Breakout:
	  		  	
	Disenrolled - Cost	  	0	  	#DIV/0!
	Disenrolled - Refused Shipment	  	0	  	#DIV/0!
	Disenrolled - MD Credential	  	0	  	#DIV/0!
	Disenrolled - Drug/Medical Concern	  	0	  	#DIV/0!
	Disenrolled - Insurance Denial	  	0	  	#DIV/0!

  

 D-3 
 [ *
] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

					
	 Disenrolled - Pt. Expired
	  	0	  	#DIV/0!
	 Disenrolled - Dr. not responding
	  	0	  	#DIV/0!
	 Disenrolled - Physician Request
	  	0	  	#DIV/0!
	 Disenrolled - Voluntarily
	  	0	  	#DIV/0!
	 Disenrolled - Unknown Reason
	  	0	  	#DIV/0!
	 Disenrolled - Unable to Contact
	  	0	  	#DIV/0!
	 Disenrolled - Prefers Alternate Therapy
	  	0	  	#DIV/0!
	 Total
	  	0	  	#DIV/0!
	 Number of Discontinued Patients
	  	0
	 Percentage of Discontinued Patients
	  	#DIV/0!
	 Discontinued Patients Breakout:
	  	
	 Discontinued - Cost
	  	
	 Discontinued - Refused Shipment
	  	
	 Discontinued - Efficacy
	  	
	 Discontinued - Drug/Medical Concern
	  	
	 Discontinued - Insurance Denial
	  	
	 Discontinued - Pt. Expired
	  	
	 Discontinued - Side Effects
	  	
	 Discontinued - Physician Request
	  	
	 Discontinued - Voluntarily
	  	
	 Discontinued - Unknown Reason
	  	
	 Discontinued - Unable to Contact
	  	
	 Discontinued - Prefers Alternate Therapy
	  	
	 Total
	  	

  

 D-4 
 [ *
] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended.Form of Restricted Stock Unit Award

 Exhibit 10.64 
 JAZZ PHARMACEUTICALS, INC. 
 RESTRICTED
STOCK UNIT GRANT NOTICE 
 (2007 EQUITY
INCENTIVE PLAN) 
 Jazz Pharmaceuticals, Inc. (the “Company”), pursuant to Section 6(b) of the
Company’s 2007 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award covering the number of restricted stock units (the “RSUs”) set forth below (the
“Award”). This Award shall be evidenced by a Restricted Stock Unit Award Agreement (the “Award Agreement”). This Award is subject to all of the terms and conditions as set forth herein and in the
applicable Award Agreement and the Plan, each of which are attached hereto and incorporated herein in their entirety. 
  

					
	Participant:	  		 	  

	RSU#	  		 	  

	Date of Grant:	  		 	  

	Vesting Commencement Date:	  		 	  

	Number of RSUs:	  		 	  

	Payment for Common Stock:	  		 	  

 Vesting Schedule: The RSUs vest in a series of four (4) successive equal annual installments
over the four (4)-year period measured from the Vesting Commencement Date. 
  

					
	Special Tax Withholding Right:	  	x	  	You may direct the Company (i) to withhold, from shares otherwise issuable upon vesting of the Award, a portion of those shares with an aggregate fair market value (measured as of the
delivery date) equal to the amount of the applicable withholding taxes, and (ii) to make a cash payment equal to such fair market value directly to the appropriate taxing authorities, as provided in Section 10 of the Award
Agreement.
			
		  	 ̈	  	None

 Delivery Schedule: Delivery of one share of Common Stock for each RSU which vests shall occur on the
applicable vesting date, provided that delivery may be delayed as provided in Section 3 of the Award Agreement. 
 Additional
Terms/Acknowledgements: Participant acknowledges receipt of, and understands and agrees to, this Grant Notice, the Award Agreement and the Plan. Participant further acknowledges that as of the date of grant, this Grant Notice, the Award
Agreement and the Plan set forth the entire understanding between Participant and the Company regarding the award of the RSUs and the underlying Common Stock and supersede all prior oral and written agreements on that subject. 
  

									
	JAZZ PHARMACEUTICALS, INC.	 		 		 	
					
	By:	 	  
	 		 		 	  

		 	Signature	 		 		 	Signature
					
	Title:	 	  
	 		 	Print Name:	 	  

					
	Date:	 	  
	 		 	Date:	 	  

 JAZZ PHARMACEUTICALS, INC. 
 2007 EQUITY INCENTIVE PLAN 
 RESTRICTED STOCK UNIT AWARD AGREEMENT 
 Pursuant to the Restricted Stock Unit Grant Notice (“Grant Notice”) and this Restricted Stock Unit Award Agreement (“Agreement”), Jazz Pharmaceuticals, Inc. (the
“Company”) has awarded you a Restricted Stock Unit Award pursuant to the Company’s 2007 Equity Incentive Plan (the “Plan”) for the number of restricted stock units (“RSUs”)
as indicated in the Grant Notice (collectively, the “Award”). Defined terms not explicitly defined in this Agreement but defined in the Plan shall have the same definitions as in the Plan. Subject to adjustment and the terms
and conditions as provided herein and in the Plan, each RSU shall represent the right to receive one (1) share of Common Stock. 
 The
details of your Award, in addition to those set forth in the Grant Notice, are as follows. 
 1. NUMBER OF
RSUS AND SHARES OF COMMON STOCK. 
 (a)
The number of RSUs subject to your Award and the number of shares of Common Stock deliverable with respect to such RSUs may be adjusted from time to time for Capitalization Adjustments as described in Section 9(a) of the Plan. You shall
receive no benefit or adjustment to your Award with respect to any cash dividend or other distribution that does not result from a Capitalization Adjustment as described in Section 9(a) of the Plan; provided, however, that this sentence
shall not apply with respect to any shares of Common Stock that are delivered to you in connection with your Award after such shares have been delivered to you. 
 (b) Any additional RSUs, shares of Common Stock, cash or other property that becomes subject to the Award pursuant to this Section 1 shall be subject, in a manner determined by the Board, to the same
forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other RSUs and Common Stock covered by your Award. 
 (c) Notwithstanding the provisions of this Section 1, no fractional RSUs or rights for fractional shares of Common Stock shall be created pursuant to this Section 1. The Board shall, in its
discretion, determine an equivalent benefit for any fractional RSUs or fractional shares that might be created by the adjustments referred to in this Section 1. 
 2. VESTING. Except as provided in Section 11, the RSUs shall vest, if at all, as provided in the Vesting Schedule set forth in your Grant Notice, provided that
vesting shall cease upon the termination of your Continuous Service. 
 3. DELIVERY OF SHARES
OF COMMON STOCK. 
 (a) Subject to the provisions of this Award Agreement and the
Plan, in the event one or more RSUs vests, the Company shall deliver to you one (1) share of Common Stock for each RSU that vests on the applicable vesting date. However, if a scheduled delivery date falls on a date that is not a business day,
such delivery date shall instead fall on the next following business day. 

 (b) Notwithstanding the foregoing, in the event that you are subject to the Company’s
Policy Regarding Stock Trading by Officers, Directors and Other Designated Employees (or any successor policy) and any shares covered by your Award are scheduled to be delivered on a day (the “Original Delivery Date”)
that does not occur during an open “window period” applicable to you, as determined by the Company in accordance with such policy, then such shares shall not be delivered on such Original Delivery Date and shall instead be delivered on the
first business day of the next occurring open “window period” but in no event later than the later of: (i) December 31st of the calendar year of the Original Delivery Date, or (ii) the fifteenth (15th) day of the third
calendar month following the Original Delivery Date. The form of such delivery (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company. 
 4. PAYMENT BY YOU. This Award was granted in consideration of your
services for the Company. Subject to Section 10 below, except as otherwise provided in the Grant Notice, you will not be required to make any payment to the Company (other than your past and future services for the Company) with respect to your
receipt of the Award, vesting of the RSUs, or the delivery of the shares of Common Stock underlying the RSUs. 
 5.
SECURITIES LAW COMPLIANCE. You may not be issued any Common Stock under your Award unless either (i) the shares of Common Stock are then registered under the
Securities Act, or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Your Award must also comply with other applicable laws and regulations governing the Award, and you
shall not receive such Common Stock if the Company determines that such receipt would not be in material compliance with such laws and regulations. 
 6. RESTRICTIVE LEGENDS. The Common Stock issued under your Award shall be endorsed with appropriate legends, if any, determined by the Company. 
 7. TRANSFER RESTRICTIONS. Prior to the time that shares of Common Stock have been delivered to you, you may not
transfer, pledge, sell or otherwise dispose of the shares in respect of your Award. For example, you may not use shares that may be issued in respect of your RSUs as security for a loan, nor may you transfer, pledge, sell or otherwise dispose of
such shares. This restriction on transfer will lapse upon delivery to you of shares in respect of your vested RSUs. Your Award is not transferable, except by will or by the laws of descent and distribution. Notwithstanding the foregoing, by
delivering written notice to the Company, in a form satisfactory to the Company, you may designate a third party who, in the event of your death, shall thereafter be entitled to receive any distribution of Common Stock to which you were entitled at
the time of your death pursuant to this Agreement. 
 8. AWARD NOT A SERVICE
CONTRACT. Your Award is not an employment or service contract, and nothing in your Award shall be deemed to create in any way whatsoever any obligation on your part to continue in the service of the
Company or any Affiliate, or on the part of the Company or any Affiliate to continue such service. In addition, nothing in your Award shall obligate the Company or any Affiliate, their respective stockholders, boards of directors or employees to
continue any relationship that you might have as an Employee or Consultant of the Company or any Affiliate. 

 9. UNSECURED OBLIGATION. Your Award is
unfunded, and even as to any RSUs that vest, you shall be considered an unsecured creditor of the Company with respect to the Company’s obligation, if any, to issue Common Stock pursuant to this Agreement. You shall not have voting or any other
rights as a stockholder of the Company with respect to the Common Stock acquired pursuant to this Agreement until such Common Stock is issued to you pursuant to Section 3 of this Agreement. Upon such issuance, you will obtain full voting and
other rights as a stockholder of the Company with respect to the Common Stock so issued. Nothing contained in this Agreement, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind or a fiduciary
relationship between you and the Company or any other person. 
 10. WITHHOLDING OBLIGATIONS.

 (a) On or before the time you receive a distribution of Common Stock pursuant to your Award, or at any time thereafter as requested
by the Company, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax withholding
obligations of the Company or any Affiliate which arise in connection with your Award (the “Withholding Taxes”). If specified in your Grant Notice, you may direct the Company to withhold shares of Common Stock with a Fair
Market Value (measured as of the date shares of Common Stock are delivered pursuant to Section 3) equal to the amount of such Withholding Taxes; provided, however, that the number of such shares of Common Stock so withheld shall not
exceed the amount necessary to satisfy the Company’s required tax withholding obligations using the minimum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to
supplemental taxable income. 
 (b) Unless the tax withholding obligations of the Company and/or any Affiliate are satisfied, the
Company shall have no obligation to deliver to you any Common Stock. 
 11. CHANGE IN
CONTROL. 
 (a) If your Continuous Service terminates either within twelve (12) months following or one
(1) month prior to the effective date of a Change in Control due to an Involuntary Termination Without Cause, the vesting of the RSUs subject to this Award shall be accelerated in full. 
 (b) For purposes of this Agreement, “Involuntary Termination Without Cause” means the involuntary termination of your
Continuous Service for reasons other than death, Disability, or Cause. For this purpose, “Cause” means that, in the reasonable determination of the Company, you have (i) committed an intentional act or acted with gross negligence that
has materially injured the business of the Company; (ii) intentionally refused or failed to follow lawful and reasonable directions of the Board or the appropriate individual to whom you report; (iii) willfully and habitually neglected
your duties for the Company; or (iv) been convicted of a felony involving moral turpitude that is likely to inflict or has inflicted material injury on the business of the Company. Notwithstanding the foregoing, Cause shall not 

 
exist based on conduct described in clause (ii) or (iii) unless the conduct described in such clause has not been cured within fifteen
(15) days following your receipt of written notice from the Company specifying the particulars of the conduct constituting Cause. Any determination by the Company that your Continuous Service was terminated by reason of dismissal without Cause
for the purposes of this Agreement shall have no effect upon any determination of the rights or obligations of you or the Company for any other purpose. 
 12. PARACHUTE PAYMENTS. 
 (a) If any
payment or benefit you would receive in connection with a Change in Control from the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the
Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Company shall cause to be determined, before any amounts of the Payment are paid to
you, which of the following two alternative forms of payment would maximize your after-tax proceeds: (i) payment in full of the entire amount of the Payment (a “Full Payment”), or (ii) payment of only a part of the
Payment so that you receive the largest payment possible without the imposition of the Excise Tax (a “Reduced Payment”), whichever amount results in your receipt, on an after-tax basis, of the greater amount of the Payment
notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. For purposes of determining whether to make a Full Payment or a Reduced Payment, the Company shall cause to be taken into account all applicable federal, state
and local income and employment taxes and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes). 

(b) If a Reduced Payment is made, (i) the Payment shall be paid only to the extent permitted under the Reduced Payment alternative, and
you shall have no rights to any additional payments and/or benefits constituting the Payment, and (ii) reduction in payments and/or benefits shall occur in the following order unless you elect in writing a different order (provided, however,
that such election shall be subject to Company approval if made on or after the date on which the event that triggers the Payment occurs): (1) reduction of cash payments; (2) cancellation of accelerated vesting of equity awards other than
stock options; (3) cancellation of accelerated vesting of stock options; and (4) reduction of other benefits paid to you. In the event that acceleration of compensation from your equity awards is to be reduced, such acceleration of vesting
shall be canceled in the reverse order of the date of grant (i.e., earliest granted Stock Award cancelled last) unless you elect in writing a different order for cancellation. 
 (c) The accounting firm engaged by the Company for general tax purposes as of the day prior to the effective date of the Change in Control shall
perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized
accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. 
 (d) The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting
documentation, to you and the 

 
Company within fifteen (15) calendar days after the date on which your right to a Payment is triggered (if requested at that time by you or the Company)
or such other time as requested by you or the Company. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish you and the Company with
an opinion reasonably acceptable to you that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon you and the Company. 

13. NOTICES. Any notices required to be given or delivered to the Company under the terms of this
Award shall be in writing and addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to you shall be in writing and addressed to your address as on file with the Company at the time notice is given.
All notices shall be deemed effective upon personal delivery or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified. 
 14. HEADINGS. The headings of the Sections in this Agreement are inserted for convenience only and shall not be deemed to constitute a part of this Agreement or to affect the meaning of this
Agreement. 
 15. AMENDMENT. This Agreement may be amended only by a writing executed by the Company and you which
specifically states that it is amending this Agreement. Notwithstanding the foregoing, this Agreement may be amended solely by the Company by a writing which specifically states that it is amending this Agreement, so long as a copy of such amendment
is delivered to you, and provided that no such amendment adversely affecting your rights hereunder may be made without your written consent. Without limiting the foregoing, the Company reserves the right to change, by written notice to you, the
provisions of this Agreement in any way it may deem necessary or advisable to carry out the purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision, provided that
any such change shall be applicable only to rights relating to that portion of the Award that has not been delivered to you in Common Stock pursuant to Section 3. 
 16. MISCELLANEOUS. 
 (a) The rights and obligations of the Company under your
Award shall be transferable by the Company to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by the Company’s successors and assigns. 
 (b) You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to
carry out the purposes or intent of your Award. 
 (c) You acknowledge and agree that you have reviewed your Award in its entirety,
have had an opportunity to obtain the advice of counsel prior to executing and accepting your Award and fully understand all provisions of your Award. 

 (d) This Agreement shall be subject to all applicable laws, rules, and regulations, and to such
approvals by any governmental agencies or national securities exchanges as may be required. 
 (e) All obligations of the Company
under the Plan and this Agreement shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the
business and/or assets of the Company. 
 17. GOVERNING PLAN
DOCUMENT. Your Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and
regulations which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of your Award and those of the Plan, the provisions of the Plan shall control; provided, however,
that Section 3 of this Agreement shall govern the timing of any distribution of Common Stock under your Award. The Company shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration,
interpretation, and application of the Plan as are consistent therewith and to interpret or revoke any such rules. All actions taken and all interpretations and determinations made by the Board shall be final and binding upon you, the Company, and
all other interested persons. No member of the Board shall be personally liable for any action, determination, or interpretation made in good faith with respect to the Plan or this Agreement. 
 18. EFFECT ON OTHER EMPLOYEE BENEFIT PLANS. The value of
the Award subject to this Agreement shall not be included as compensation, earnings, salaries, or other similar terms used when calculating benefits under any employee benefit plan (other than the Plan) sponsored by the Company or any Affiliate
except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any or all of the employee benefit plans of the Company or any Affiliate. 
 19. CHOICE OF LAW. The interpretation, performance and enforcement of this Agreement shall be
governed by the law of the state of California without regard to such state’s conflicts of laws rules. 
 20.
SEVERABILITY. If all or any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Agreement or the
Plan not declared to be unlawful or invalid. Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of
a Section to the fullest extent possible while remaining lawful and valid. 
 21. OTHER DOCUMENTS. You
hereby acknowledge receipt or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act (which includes the prospectus for the Plan). In addition, you acknowledge receipt of the
Company’s Policy Regarding Stock Trading by Officers, Directors and Other Designated Employees and the Company’s Insider Trading Policy. 

 * * * * * 
 This Restricted Stock Unit Award Agreement shall be deemed to be signed by the Company and you upon the signing by you of the Restricted Stock Unit Grant Notice to which it is attached.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}]]